Finance

Lists
Q3 2026 earnings • in 4 days
See details
COGT:NASDAQ
Cogent Biosciences Inc
$29.53
-6.22%
(-1.96) 1D
Nov 5, 11:00:55 AM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for COGT...
Open
$31.34
High
$31.41
Low
$29.16
Mkt. cap
5.15B
Avg. vol.
2.16M
Volume
695.33K
52-wk high
$43.73
52-wk low
$13.93
EPS
-$2.14
Beta
0.36
Shares outstanding
173.52M
No. of employees
258
Open
$31.34
High
$31.41
Low
$29.16
Mkt. cap
5.15B
Avg. vol.
2.16M
Volume
695.33K
52-wk high
$43.73
52-wk low
$13.93
EPS
-$2.14
Beta
0.36
Shares outstanding
173.52M
No. of employees
258
News stories
From web sources and news partners
About Cogent Biosciences Inc
CEO-
Employees258
Founded2014
HeadquartersWaltham, Massachusetts, United States
SectorBiotechnology
Industry-
Websitecogentbio.com
Analyst ratings
Based on 9 analysts giving stock ratings to COGT in the past 3 months
Strong buy
Buy
8
Hold
1
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for COGT in the last 3 months.
Highest
Current $29.53
$62.00 (+109.96%)
Average
$54.88 (+85.84%)
Lowest
$45.00 (+52.39%)
Analyst
Recommendation
Action
Price target
Projected
Date
Laura Prendergast
Stifel Nicolaus
Buy
Maintained
$45.00
+52.4%
10/27/2026
Michael Yee
UBS
Buy
Maintained
$60.00
+103.2%
10/13/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$52.00
+76.1%
10/06/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$52.00
+76.1%
10/06/2026
David Nierengarten
Wedbush
Buy
Maintained
$55.00
+86.3%
09/16/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$55.00
+86.3%
09/15/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$55.00
+86.3%
09/16/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
$62.00
+110%
09/09/2026
Allison Bratzel
Piper Sandler
Buy
Maintained
$55.00
+86.3%
08/17/2026
Ami Fadia
Needham
Hold
Reiterated
-
-
08/11/2026
Faisal Khurshid
Jefferies
Buy
Initiated
$55.00
+86.3%
03/16/2026
Colleen M. Kusy
Robert W. Baird
Hold
Maintained
$35.00
+18.5%
02/19/2026
Next call in 4 days
Mon, Nov 9, 7:30 PM
Fiscal period
Q3 2026
- / -$0.55
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
68.99M
75.56M
75.36M
70.81M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
14.37M
23.93M
28.24M
31.83M
Operating expense
83.36M
99.49M
103.61M
102.64M
Total operating expenses
83.36M
99.49M
103.61M
102.64M
Operating income
-83.36M
-99.49M
-103.61M
-102.64M
Other non operating income
-3.00K
900.00K
-140.00K
-11.00K
EBT including unusual items
-80.93M
-102.49M
-97.35M
-96.40M
EBT excluding unusual items
-80.93M
-94.40M
-97.35M
-96.40M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-80.93M
-102.49M
-97.35M
-96.40M
Net profit margin
-
-
-
-
Earnings per share
-0.50
-0.56
-0.53
-0.52
Interest and investment income
3.89M
5.48M
7.61M
7.46M
Interest expense
-1.46M
-1.29M
-1.21M
-1.22M
Net interest expenses
2.43M
4.19M
6.40M
6.24M
Depreciation and amortization charges
-
-
-
-
EBITDA
-82.71M
-98.86M
-102.98M
-101.90M
Gain or loss from assets sale
-
-
135.00K
-1.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps